Venture&Growth
![](https://gildehealthcare.com/wp-content/uploads/2021/06/MTM.png)
Location
Heidelberg, Germany
Venture&Growth
All Portfolio items
See full Venture&Growth portfolio
mtm laboratories manufactures and commercializes in-vitro diagnostic tests for the analysis of cervical cancer. Worldwide, cervical cancer is the second most common cancer in women. mtm’s CINtec® technology detects a specific cellular biomarker (p16INK4a) and offers the potential for highly specific and accurate diagnosis of early-stage cervical cancer, even if it is without symptoms.
Since Gilde invested in mtm laboratories, the German company has clinically validated its diagnostic products and more than doubled its sales. mtm laboratories was acquired by Roche in 2011.
More mtm laboratories news
Study of CINtec® PLUS in the management of Pap negative but HPV positive women published
mtm laboratories Extends Series C Financing Round by EUR 7 Million ($9.7 Million)
MTM Laboratories – p16 Immuno-cytochemistry shows superior clinical performance to HPV testing
mtm’s CINtec® PLUS, delivers new solution to manage Pap negative but HPV positive women
mtm laboratories Announces the European Launch of CINtec(R) PLUS
MTM LABORATORIES – CINtec® p16 Histology test increases accuracy in diagnosing
GILDE HEALTHCARE II invests in mtm laboratories AG
Shoulder Innovations
Shoulder Innovations is a medical device company that is commercializing a novel shoulder arthroplasty portfolio...
![](https://gildehealthcare.com/wp-content/uploads/2023/03/SI-Logo-2.png)
Inari Medical
US MedTech company focused on removal of blood clots to treat pulmonary embolism or deep...
![](https://gildehealthcare.com/wp-content/uploads/2021/05/Inari.png)
Volta Medical
French Healthtech company developing AI software solutions to assist in cardiac operations.
![](https://gildehealthcare.com/wp-content/uploads/2021/05/Volta.png)